» Articles » PMID: 14985067

In Vivo Electrophysiological Effects of a Selective Slow Delayed-rectifier Potassium Channel Blocker in Anesthetized Dogs: Potential Insights into Class III Actions

Overview
Journal Cardiovasc Res
Date 2004 Feb 27
PMID 14985067
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study evaluated the in vivo electrophysiological effects of a highly selective slow delayed-rectifier K+-current blocker, HMR 1556, to gain insights into the consequences of selectively inhibiting the slow delayed-rectifier current in vivo.

Methods: Atrial and ventricular effective refractory periods, sinus node recovery time, Wenckebach cycle-length, atrial fibrillation duration and electrocardiographic intervals were measured before and after intravenous HMR 1556.

Results: HMR 1556 increased atrial and ventricular refractory periods (e.g. by 6 +/- 4% and 27 +/- 6% at cycle lengths of 360 and 400 ms, respectively), QT intervals and sinus-node recovery times. Beta-adrenoceptor blockade with nadolol abolished all effects except those on ventricular refractoriness and changed positive use-dependent effects on refractoriness to reverse use-dependent ones. In the presence of dofetilide to block rapid delayed-rectifier current, HMR 1556 effects were potentiated (e.g. atrial and ventricular refractory periods increased by 26 +/- 3% and 34 +/- 3% at cycle lengths of 360 and 400 ms, respectively). HMR 1556 reduced vagal atrial fibrillation duration from 1077 +/- 81 to 471 +/- 38 s, an effect abolished by nadolol and greatly potentiated by dofetilide (duration 77 +/- 30 s). HMR 1556 increased Wenckebach cycle length only in the presence of dofetilide.

Conclusions: Slowed delayed-rectifier current inhibition affects atrial repolarization, sinus node function and atrial fibrillation in vivo, but only in the presence of intact beta-adrenergic tone, and delays ventricular repolarization even when beta-adrenoceptors are blocked. The slow delayed-rectifier current is particularly important when rapid delayed-rectifier current is suppressed, illustrating the importance of repolarization reserve.

Citing Articles

New Strategies for the Treatment of Atrial Fibrillation.

Jost N, Christ T, Magyar J Pharmaceuticals (Basel). 2021; 14(9).

PMID: 34577626 PMC: 8466466. DOI: 10.3390/ph14090926.


Beta-adrenergic stimulation reverses the I Kr-I Ks dominant pattern during cardiac action potential.

Banyasz T, Jian Z, Horvath B, Khabbaz S, Izu L, Chen-Izu Y Pflugers Arch. 2014; 466(11):2067-76.

PMID: 24535581 PMC: 4138296. DOI: 10.1007/s00424-014-1465-7.


Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation.

Campbell C, Campbell J, Thompson C, Savio Galimberti E, Darbar D, Vanoye C Circ Arrhythm Electrophysiol. 2013; 6(5):960-6.

PMID: 24006450 PMC: 3892565. DOI: 10.1161/CIRCEP.113.000439.


Gene-specific effect of beta-adrenergic blockade on corrected QT interval in the long QT syndrome.

Extramiana F, Maison-Blanche P, Denjoy I, De Jode P, Messali A, Labbe J Ann Noninvasive Electrocardiol. 2013; 18(4):399-408.

PMID: 23879280 PMC: 6932500. DOI: 10.1111/anec.12048.


Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Workman A, Smith G, Rankin A Pharmacol Ther. 2011; 131(2):221-41.

PMID: 21334377 PMC: 3173850. DOI: 10.1016/j.pharmthera.2011.02.002.